<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180113038328N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-02-17</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of Autologous Serum Therapy in Chronic Spontaneous Urticaria</public_title>
      <acronym></acronym>
      <scientific_title>The Effect of Autologous Serum Therapy on Chronic Spontaneous Urticaria; Clinical Symptoms and Immunologic Changes</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2014-09-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/29010</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Chronic spontaneous urticaria.</hc_freetext>
      <i_freetext>Intervention group1: Treatment with autologous serum therapy  in chronic autoimmune urticaria(  group 1) was performed weekly for 10 weeks. At each visit, 5 cc of venous blood was taken in sterile size 10 Falcon tubes, without EDTA anticoagulant. Blood samples were then kept at room temperature for 30 minutes to complete the blood coagulation. The serum was then isolated by centrifuging at 2000 rpm for 10 minutes. Immediately after the conclusion of isolation deep intramuscular injection of 2 cc of the centrifuged serum was performed in sterile conditions in buttock or arm area. To evaluate the effect of autologous serum therapy on clinical improvement of patients, urticaria total severity score  and dermatology quality of life index  questionnaire were used before treatment (week 0), at the end of treatment (week 10) and one month after treatment (week 14).Before starting and immediately after the completion of autologous serum therapy (weeks 0 and 10), 5 cc of venous blood from 20 randomly selected patients in chronic autoimmune urticaria( group1) was extracted for immunological examination. Then the expression of IL-17, IL-10, IL-4, FOXP3and INF-γ genes was evaluated  by Real -time PCR.Intervention group2:Treatment with autologous serum therapy  in chronic idiopathic  urticaria(  group 2) was performed weekly for 10 weeks. At each visit, 5 cc of venous blood was taken in sterile size 10 Falcon tubes, without EDTA anticoagulant. Blood samples were then kept at room temperature for 30 minutes to complete the blood coagulation. The serum was then isolated by centrifuging at 2000 rpm for 10 minutes. Immediately after the conclusion of isolation deep intramuscular injection of 2 cc of the centrifuged serum was performed in sterile conditions in buttock or arm area. To evaluate the effect of autologous serum therapy on clinical improvement of patients, urticaria total severity score  and dermatology quality of life index questionnaire were used before treatment (week 0), at the end of treatment (week 10) and one month after treatment (week 14).Before starting and immediately after the completion of autologous serum therapy (weeks 0 and 10), 5 cc of venous blood from 20 randomly selected patients in chronic idiopathic urticaria( group2) was extracted for immunological examination. Then the expression of IL-17, IL-10, IL-4, FOXP3and INF-γ genes was evaluated  by Real -time PCR..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Total non-identifiable data, the potential of the people sharing

When:
Immediately after the publication of results

To whom:
For all researchers

Conditions:
Therapeutic and research use

Where to obtain:
Majid jafari
By email
jafari.md.ped@gmail.com

How to obtain:
Immediately after the email

Comments:
I have no comment</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Majid jafari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahmadabad Blvd,Ghaem Hospital,mashhad Town</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>99191-91778</zip>
        <telephone>+98 51 3801 2770</telephone>
        <email>jafari.md.ped@gmail.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Majid jafari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Ahmadabad Blvd,Ghaem Hospital,mashhad Town</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>91766-99199</zip>
        <telephone>+98 51 3801 2770</telephone>
        <email>jafari.md.ped@gmail.com</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Symptoms lasting more than 6 weeks
Negative Prick test for oral and inhalatory allergens
Aged higher than 15 years
Normal laboratory result for CBC/diff - S/E - U/A-LFT-HBsAg-BUN-Cr-ESR-CRP-CH50-ANA-IgE and anti-Helicobacter pylori tests</inclusion_criteria>
      <agemin>15 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Physical urticaria
Allergic and drug urticaria
Vasculitis urticaria
Cortisone and immunosuppressive use over the past 6 weeks (other than antihistamines)
Pregnancy
Lactation
Other systemic diseases.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L50.8</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other urticaria</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: Treatment with autologous serum therapy  in chronic autoimmune urticaria(  group 1) was performed weekly for 10 weeks. At each visit, 5 cc of venous blood was taken in sterile size 10 Falcon tubes, without EDTA anticoagulant. Blood samples were then kept at room temperature for 30 minutes to complete the blood coagulation. The serum was then isolated by centrifuging at 2000 rpm for 10 minutes. Immediately after the conclusion of isolation deep intramuscular injection of 2 cc of the centrifuged serum was performed in sterile conditions in buttock or arm area. To evaluate the effect of autologous serum therapy on clinical improvement of patients, urticaria total severity score  and dermatology quality of life index  questionnaire were used before treatment (week 0), at the end of treatment (week 10) and one month after treatment (week 14).Before starting and immediately after the completion of autologous serum therapy (weeks 0 and 10), 5 cc of venous blood from 20 randomly selected patients in chronic autoimmune urticaria( group1) was extracted for immunological examination. Then the expression of IL-17, IL-10, IL-4, FOXP3and INF-γ genes was evaluated  by Real -time PCR.Intervention group2:Treatment with autologous serum therapy  in chronic idiopathic  urticaria(  group 2) was performed weekly for 10 weeks. At each visit, 5 cc of venous blood was taken in sterile size 10 Falcon tubes, without EDTA anticoagulant. Blood samples were then kept at room temperature for 30 minutes to complete the blood coagulation. The serum was then isolated by centrifuging at 2000 rpm for 10 minutes. Immediately after the conclusion of isolation deep intramuscular injection of 2 cc of the centrifuged serum was performed in sterile conditions in buttock or arm area. To evaluate the effect of autologous serum therapy on clinical improvement of patients, urticaria total severity score  and dermatology quality of life index questionnaire were used before treatment (week 0), at the end of treatment (week 10) and one month after treatment (week 14).Before starting and immediately after the completion of autologous serum therapy (weeks 0 and 10), 5 cc of venous blood from 20 randomly selected patients in chronic idiopathic urticaria( group2) was extracted for immunological examination. Then the expression of IL-17, IL-10, IL-4, FOXP3and INF-γ genes was evaluated  by Real -time PCR.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Spontaneous chronic urticaria is a qualitative variable with clinical parameters and cytokines is a of quantity Variable that is measured with PCR. Timepoint: Before and after treatment, as well as 4 weeks after the completion of treatment. Method of measurement: Urticaria total severity score (TSS) ,dermatology quality of life index (DLQI),Real-time-PCR.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2013-09-11</approval_date>
        <contact_name>Ethics Committee of Mashhad University of Medical Sciences</contact_name>
        <contact_address>Knowledge and Health city, In the end of shahid Fakouri Blvd.mashhad Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
